Selective proteasome inhibitors : modulators of antigen presentation?

Gröttrup, Marcus; Schmidtke, Gunter

Selective proteasome inhibitors : modulators of antigen presentation?

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

1999

Publikationstyp

Zeitschriftenartikel

unikn.publication.listelement.citation.prefix.version.undefined

Drug Discovery Today. 1999, 4(2), pp. 63-71. ISSN 1359-6446. eISSN 1878-5832. Available under: doi: 10.1016/S1359-6446(98)01292-6

Zusammenfassung

The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.

Fachgebiet (DDC)

570 Biowissenschaften, Biologie

Zitieren

ISO 690

GRÖTTRUP, Marcus, Gunter SCHMIDTKE, 1999. Selective proteasome inhibitors : modulators of antigen presentation?. In: Drug Discovery Today. 1999, 4(2), pp. 63-71. ISSN 1359-6446. eISSN 1878-5832. Available under: doi: 10.1016/S1359-6446(98)01292-6

BibTex

@article{Grottrup1999Selec-22238,
  year={1999},
  doi={10.1016/S1359-6446(98)01292-6},
  title={Selective proteasome inhibitors : modulators of antigen presentation?},
  number={2},
  volume={4},
  issn={1359-6446},
  journal={Drug Discovery Today},
  pages={63--71},
  author={Gröttrup, Marcus and Schmidtke, Gunter}
}

RDF

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/22238">
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:title>Selective proteasome inhibitors : modulators of antigen presentation?</dcterms:title>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T13:34:18Z</dcterms:available>
    <dcterms:bibliographicCitation>Drug Discovery Today ; 4 (1999), 2. - S. 63-71</dcterms:bibliographicCitation>
    <dc:language>eng</dc:language>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Schmidtke, Gunter</dc:contributor>
    <dcterms:issued>1999</dcterms:issued>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T13:34:18Z</dc:date>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Schmidtke, Gunter</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:abstract xml:lang="eng">The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.</dcterms:abstract>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22238"/>
  </rdf:Description>
</rdf:RDF>

Universitätsbibliographie

Nein